Skip to main content

Table 4 Heterogeneity analysis of meta-analyses (outcome included sensitivity analysis and meta-regression) for furosemide stress test as a renal replacement therapy prediction tool

From: Furosemide stress test as a predictive marker of acute kidney injury progression or renal replacement therapy: a systemic review and meta-analysis

Variables

Subgroups

Number of studies

Sensitivity (95% CI)

Specificity (95% CI)

Positive LR (95% CI)

Negative LR (95% CI)

Diagnostic odds ratio (95% CI)

Coeff.

SE

P value

RDOR (95% CI)

RRT rate

< 20%

2

0.80 (0.57–0.92)

0.82 (0.73–0.88)

4.35 (2.66–7.10)

0.25 (0.11–0.61)

17.52 (5.16–59.44)

0.17

0.59

0.77

1.19 (0.37–3.78)

≥ 20%

4

0.85 (0.69–0.93)

0.76 (0.54–0.89)

2.64 (1.62–4.32)

0.25 (0.12–0.51)

12.81 (4.19–39.12)

Follow-up duration

Not reported or < 7 days

3

0.80 (0.74–0.8 5)

0.74 (0.52–0.89)

2.89 (1.49–5.57)

0.37 (0.28–0.50)

4.97 (3.32–7.44)

1.31

0.78

0.09

3.71 (0.80–71.11)

≥ 7 days

3

0.91 (0.66–0.98)

0.77 (0.65–0.86)

3.42 (2.41–4.86)

0.15 (0.07–0.34)

30.46 (13.13–70.66)

AKI stage enrolled

Stage 3

1

     

1.75

0.43

< 0.01

5.75 (2.51–13.33)

Stage 1 or 2

5

0.85 (0.68–0.94)

0.80 (0.73–0.86)

3.77 (2.80–5.09)

0.21 (0.11–0.41)

24.93 (12.45–49.91)

  1. Abbreviation: AKI acute kidney injury, LR likelihood ratio, RDOR relative diagnostic odds ratio, RRT renal replacement therapy, SE standard error, UOP urine output